Cargando…

Are patients willing to incur out of pocket costs for pharmacogenomic testing?

Detalles Bibliográficos
Autores principales:	Bielinski, Suzette J., St. Sauver, Jennifer L., Olson, Janet E., Wieland, Mark L., Vitek, Carolyn R., Bell, Elizabeth J., McGree, Michaela E., Jacobson, Debra J., McCormick, Jennifer B., Takahashi, Paul Y., Black, John L., Caraballo, Pedro J., Sharp, Richard R., Beebe, Timothy J., Weinshilboum, Richard M., Wang, Liewei, Roger, Véronique L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310981/ https://www.ncbi.nlm.nih.gov/pubmed/27779246 http://dx.doi.org/10.1038/tpj.2016.72

Ejemplares similares

Participant perceived understanding and perspectives toward pharmacogenomics: Mayo Clinic Right Drug, Right Dose, Right Time (RIGHT) Protocol
por: Olson, Janet E., et al.
Publicado: (2017)

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
por: Zhu, Ye, et al.
Publicado: (2019)

Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events
por: Zhu, Ye, et al.
Publicado: (2021)

Multidisciplinary Model to Implement Pharmacogenomics at the Point of Care
por: Caraballo, Pedro J., et al.
Publicado: (2016)

An assessment of patient perspectives on pharmacogenomics educational materials
por: Asiedu, Gladys B, et al.
Publicado: (2020)

Pharmacogenomics in Practice
por: Wang, Liewei, et al.
Publicado: (2019)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
por: Zhu, Ye, et al.
Publicado: (2020)

Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare
por: Giri, Jyothsna, et al.
Publicado: (2019)

Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort
por: Swanson, Kristi M., et al.
Publicado: (2020)

Cohort study examining associations between ceramide levels and risk of multimorbidity among persons participating in the Mayo Clinic Biobank
por: St Sauver, Jennifer L, et al.
Publicado: (2023)

Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study
por: Wang, Liewei, et al.
Publicado: (2017)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics
por: Takahashi, Paul Y, et al.
Publicado: (2014)

Inflammatory biomarkers, multi-morbidity, and biologic aging
por: St. Sauver, Jennifer, et al.
Publicado: (2022)

Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Response to Letter]
por: Takahashi, Paul Y, et al.
Publicado: (2021)

CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications
por: St Sauver, Jennifer L, et al.
Publicado: (2017)

Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis
por: Breitenstein, Matthew K., et al.
Publicado: (2015)

Implementing the US Department of Health and Human Services definition of multimorbidity: a comparison between billing codes and medical record review in a population-based sample of persons 40–84 years old
por: St Sauver, Jennifer L, et al.
Publicado: (2021)

Modelling survival data to account for model uncertainty: a single model or model averaging?
por: Thamrin, Sri Astuti, et al.
Publicado: (2013)

Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
por: Lopes, Guilherme S, et al.
Publicado: (2020)

Willing to Be Involved in Cancer
por: Gunn-Moore, Frank J., et al.
Publicado: (2016)

Wills, Living Wills and Enduring Powers of Attorney
por: Laurence, D R
Publicado: (1995)

No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study
por: Takahashi, Paul Y, et al.
Publicado: (2021)

The Impact of Spatial Scales and Spatial Smoothing on the Outcome of Bayesian Spatial Model
por: Kang, Su Yun, et al.
Publicado: (2013)

A patient-centered approach to the development and pilot of a warfarin pharmacogenomics patient education tool for health professionals
por: Barajas, Megan R., et al.
Publicado: (2015)

The Wills eye hospital : Vademécum oftalmológico de medicamentos /
por: Rhee, Douglas J.
Publicado: (2000)

Flawed but Willing
por: Dehnugara, Khurshed
Publicado: (2015)

Doctors' Wills
Publicado: (1914)

Doctors' Wills
Publicado: (1914)

Doctors' Wills
Publicado: (1914)

Doctors' Wills
Publicado: (1914)

Doctors' Wills
Publicado: (1914)

Doctors' Wills
Publicado: (1914)

Doctor's Wills
Publicado: (1914)

Doctors' Wills
Publicado: (1914)

Doctors' Wills
Publicado: (1914)

Doctor's Wills
Publicado: (1913)

Doctors' Wills
Publicado: (1914)

Living Wills
por: Jessiman, Ian
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_na0kr4llfjmp22057esr3lu81m